Drug
Fasudil
Fasudil is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(17%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
1
17%
Ph phase_2
5
83%
Phase Distribution
0
Early Stage
5
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(3)
Other(2)
Detailed Status
Completed3
unknown2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 25 (83.3%)
Phase 31 (16.7%)
Trials by Status
unknown233%
completed350%
recruiting117%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_2
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
NCT06362707
completedphase_2
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
NCT03792490
unknownphase_2
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
NCT04734379
completedphase_3
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
NCT00498615
unknownphase_2
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01935518
Clinical Trials (6)
Showing 6 of 6 trials
NCT06362707Phase 2
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
NCT03792490Phase 2
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
NCT04734379Phase 2
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
NCT00498615Phase 3
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
NCT01935518Phase 2
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00120718Phase 2
The Effect of Fasudil on Vascular Function in Humans
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6